Literature DB >> 12441718

Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy.

Richard F Spaide1, K Bailey Freund, Jason Slakter, John Sorenson, Lawrence A Yannuzzi, Yale Fisher.   

Abstract

PURPOSE: To study the effects of photodynamic therapy (PDT) using verteporfin on the treatment of patients with subfoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis and panuveitis (MCP), an uncommon disorder with no proven forms of therapy.
METHODS: A retrospective chart review of seven consecutive patients with subfoveal CNV secondary to MCP treated with PDT using verteporfin was performed.
RESULTS: The mean age of the 7 patients (all myopic women) was 41.4 years. A mean of 1.86 treatments was performed, and the mean follow-up time was 10 months. Four of the seven patients were treated unsuccessfully with corticosteroids before referral for PDT. The mean improvement of visual acuity was 0.86 line; 3 patients (42.8%) had an improvement in visual acuity representing at least a halving of their visual angle, while the other 4 patients remained stable. There were no treatment-related side effects.
CONCLUSIONS: Although the follow-up time and the number of patients in this study were limited, the use of PDT was associated with stabilization or improvement of visual acuity in patients with subfoveal CNV secondary to MCP. Further study of this treatment modality is indicated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441718     DOI: 10.1097/00006982-200210000-00003

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  17 in total

1.  Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases.

Authors:  Joachim Wachtlin; Heinrich Heimann; Tim Behme; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-11       Impact factor: 3.117

2.  Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation.

Authors:  A Hogan; U Behan; D J Kilmartin
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

3.  Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy.

Authors:  Noémi Maár; Erdem Ergun; Alexandra Luksch; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

4.  Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease.

Authors:  S R Nowilaty; M Bouhaimed
Journal:  Br J Ophthalmol       Date:  2006-05-10       Impact factor: 4.638

5.  [White dot syndromes : Principles, diagnostics, and treatment].

Authors:  Dominika Pohlmann; Sibylle Winterhalter; Uwe Pleyer
Journal:  Ophthalmologe       Date:  2019-12       Impact factor: 1.059

6.  Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression.

Authors:  T Leslie; N Lois; D Christopoulou; J A Olson; J V Forrester
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

7.  [Punctate inner choroidopathy - Improvement in vision after anti-VEGF and photodynamic therapy. An 18-month follow-up control].

Authors:  S Weiss; R Winter; M W Meyer
Journal:  Ophthalmologe       Date:  2012-02       Impact factor: 1.059

8.  Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).

Authors:  Joan W Miller
Journal:  Trans Am Ophthalmol Soc       Date:  2008

9.  Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis.

Authors:  Thi Ha Chau Tran; Christine Fardeau; Céline Terrada; Ghislaine Ducos De Lahitte; Bahram Bodaghi; Phuc Lehoang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-06       Impact factor: 3.117

Review 10.  [White dot syndrome].

Authors:  W Göbel
Journal:  Ophthalmologe       Date:  2008-01       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.